Sunshine Biopharma Inc. (SBFMW)
NasdaqCM: SBFMW
· Real-Time Price · USD
0.04
+0.00 (0.00%)
At close: Aug 04, 2026, 7:31 PM
Sunshine Biopharma Inc. (SBFMW) Stock Price, Analysis & Data
0.00% (1D)
No data available
| Bid | n/a |
| Market Cap | n/a |
| Revenue (ttm) | 35.49M |
| Net Income (ttm) | -6.04M |
| Beta | 1.31 |
| EPS (ttm) | -2.21 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | n/a |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | 0 |
| Avg. Volume (20D) | |
| Open | 0.24 |
| Previous Close | 0.04 |
| Day's Range | 0.04 - 0.04 |
| 52-Week Range | 0.04 - 0.04 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About SBFMW
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calciu...
IPO Date Jul 17, 2026
Employees 50
Stock Exchange NasdaqCM
Ticker Symbol SBFMW
Website https://sunshinebiopharma.com
Financial Performance
In 2025, Sunshine Biopharma's revenue was 36.31M, an increase of 4.11% compared to the previous year's 34.87M. Earnings were -5.98M, an increase of 16.39%.
Financial Statements